Abstract
Airborne viruses such as SARS-CoV-2 are partly spreading through aerosols containing viral particles. Inhalation of infectious airborne particles can lead to infection, a route that can even be more predominant compared with droplet or contact transmission. To study the transmission between a susceptible and an infected person, we estimate the distribution of arrival times of small diffusing aerosol particles to the inhaled region located below the nose until the number of particles reaches a critical threshold. Our results suggest that although contamination by continuous respiration can take around 90 minutes at a distance of one meter, it is reduced to a few minutes when coughing or sneezing. Interestingly, there is not much differences between outdoors and indoors when the air is still. When a window is open inside an office, the infection time is reduced. Finally, wearing a mask leads to a delay in the time to infection. To conclude, diffusion analysis provides several key time scale of viral airborne transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
U.D. was supported by a Herchel Smith Postdoctoral Fellowship and acknowledges core funding by the Wellcome Trust (092096) and CRUK (C6946/A14492). D. H. 's research has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 882673), Plan Cancer-INSERM Projet 19CS145-00 and ANR NEUC-0001.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
nothing to declare
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos